Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2.

Hepatitis C virus (HCV) is a major cause of chronic hepatitis and hepatocellular carcinoma worldwide. The purpose of this study was to determine how the HCV structural proteins affect the dynamic structural and functional properties of hepatocytes and measure the extra-hepatic manifestations induced by these viral proteins. A transgenic mouse model was established by expressing core, E1 and E2 proteins downstream of a CMV promoter. HCV RNA was detected using RT-PCR in transgenic mouse model tissues, such as liver, kidney, spleen and heart. Expression of the transgene was analysed by real-time PCR to quantify viral RNA in different tissues at different ages. Immunofluorescence analysis revealed the expression of core, E1 and E2 proteins predominantly in hepatocytes. Lower levels of protein expression were detected in spleen and kidneys. HCV RNA and viral protein expression increased in the liver with age. Histological analysis of liver cells demonstrated steatosis in transgenic mice older than 3 months, which was more progressed with age. Electron microscopy analysis revealed alterations in nuclei, mitochondria and endoplasmic reticulum. HCV structural proteins induce a severe hepatopathy in the transgenic mouse model. These mice became more prone to liver and lymphoid tumour development and hepatocellular carcinoma. In this model, the extra-hepatic effects of HCV, which included swelling of renal tubular cells, were mild. It is likely that the HCV structural proteins mediate some of the histological alterations in hepatocytes by interfering with lipid transport and liver metabolism.

[1]  M. Honda,et al.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. , 2002, Gastroenterology.

[2]  P. Marcellin,et al.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) , 1998, Lancet.

[3]  D. Tyrrell,et al.  Hepatitis C virus replication in mice with chimeric human livers , 2001, Nature Medicine.

[4]  J. Hoofnagle,et al.  Hepatitis C: The clinical spectrum of disease , 1997, Hepatology.

[5]  M. Boiocchi,et al.  Hepatitis C Virus, B-cell Proliferation and Lymphomas , 2002, Leukemia & lymphoma.

[6]  J. George,et al.  Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response , 2002, Hepatology.

[7]  S. Polyak,et al.  Treatment of chronic hepatitis C virus infection: a clinical and virological perspective. , 1996, Advances in experimental medicine and biology.

[8]  J. Hoefs,et al.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[9]  D. Wendling,et al.  Presence of hepatitis C virus RNA in the salivary glands of patients with Sjögren's syndrome and hepatitis C virus infection. , 2002, The Journal of rheumatology.

[10]  J. McLauchlan,et al.  Sequence motifs required for lipid droplet association and protein stability are unique to the hepatitis C virus core protein. , 2000, The Journal of general virology.

[11]  Darius Moradpour,et al.  Structural biology of hepatitis C virus , 2004, Hepatology.

[12]  H. Yonekawa,et al.  Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice , 2003, Cancer science.

[13]  C. Rice,et al.  Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini , 1994, Journal of virology.

[14]  S. Ueda,et al.  Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. , 2003, Comparative immunology, microbiology and infectious diseases.

[15]  E. Holmes,et al.  Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. , 1993, The Journal of general virology.

[16]  M. Honda,et al.  A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. , 2000, Transactions of the American Clinical and Climatological Association.

[17]  M. Koffler Epidemiology of hepatitis. , 1965, Lancet.

[18]  N. Kato Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. , 2000, Microbial & comparative genomics.

[19]  M. Mondelli,et al.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study , 1997, Hepatology.

[20]  T. Morizane,et al.  Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection , 1998, The Lancet.

[21]  O. Yokosuka,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.

[22]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[23]  J. Morales,et al.  Hepatitis C virus infection and renal disease after renal transplantation. , 2004, Transplantation proceedings.

[24]  R. Bartenschlager,et al.  Kinetic and structural analyses of hepatitis C virus polyprotein processing , 1994, Journal of virology.

[25]  J Cohen,et al.  The Scientific Challenge of Hepatitis C , 1999, Science.

[26]  S. Levy,et al.  V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. , 2001, Blood.

[27]  R. Purcell,et al.  Genetic heterogeneity of the hepatitis C virus. , 1995, Princess Takamatsu symposia.

[28]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[29]  K. Koike,et al.  Expression of hepatitis C virus envelope proteins in transgenic mice. , 1995, The Journal of general virology.

[30]  M. Selby,et al.  Interaction between hepatitis C virus core protein and E1 envelope protein , 1996, Journal of virology.

[31]  M. Moriyama,et al.  Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease , 2001, Hepatology.

[32]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[33]  F. Chisari Cytotoxic T cells and viral hepatitis. , 1997, The Journal of clinical investigation.

[34]  D. Pessayre,et al.  Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral‐related steatosis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  H. Yonekawa,et al.  Efficient Conditional Transgene Expression in Hepatitis C Virus cDNA Transgenic Mice Mediated by the Cre/loxP System* , 1998, The Journal of Biological Chemistry.

[36]  M. Kohara,et al.  Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates , 1999, Hepatology.

[37]  G. Migliaccio,et al.  Biosynthesis and biochemical properties of the hepatitis C virus core protein , 1994, Journal of virology.

[38]  N. Tanaka,et al.  Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis , 1996, Journal of Gastroenterology.

[39]  K. Koike,et al.  Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Tinelli,et al.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. , 1996, Gastroenterology.

[41]  D. Pateron,et al.  Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease , 1992, The Lancet.

[42]  K Koike,et al.  Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. , 1997, The Journal of general virology.

[43]  K. Eguchi,et al.  Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.

[44]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[45]  M. Makuuchi,et al.  Increase in the concentration of carbon 18 monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. , 2001, Biochemical and biophysical research communications.

[46]  K. Abid,et al.  Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. , 2000, Journal of hepatology.

[47]  Miriam J. Alter Epidemiology of hepatitis C. , 1996 .

[48]  C. Rice,et al.  Expression and identification of hepatitis C virus polyprotein cleavage products , 1993, Journal of virology.

[49]  P. Barr,et al.  Genetic organization and diversity of the hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.